Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the End Stage Renal Disease (ESRD) Drug Industry?
The market size of drugs for end stage renal disease (esrd) has experienced a fast-paced expansion in the past few years. The market, which was worth $131.41 billion in 2024, is projected to reach $148.55 billion in 2025, displaying a compound annual growth rate (CAGR) of 13.0%. The growth observed in the historical period can be attributed to factors such as the rising prevalence of end stage renal disease, an increasing elderly population, enhanced healthcare services accessibility, government initiatives and policies, and growing acceptance of renal replacement therapies.
The market for end stage renal disease (esrd) medication is anticipated to experience significant expansion in the coming years. It’s projected to increase to “$262.76 billion by 2029 with a compound annual growth rate (CAGR) of 15.3%. The expected growth during this period can be ascribed to the introduction of new therapies and drug breakthroughs, enhanced healthcare spending, the escalating worldwide impact of chronic kidney disorders, personalized treatment methodologies, regulatory backing, and accelerated approvals. Key trends predicted for this forecast period include a rising prevalence of end stage renal disease, improvements in treatment processes, heightened focus on precision medicine, the emergence of combined therapies, and technological advancements in healthcare.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What Forces Are Driving The Growth Of The End Stage Renal Disease (ESRD) Drug Industry?
The end-stage renal disease (ESRD) drug market is predicted to experience increased growth due to the escalating rates of obesity and diabetes. Obesity, which refers to the unhealthy and excessive accumulation of fat in the body, and diabetes, a chronic ailment caused by the pancreas’ inability to produce sufficient insulin or the body’s inefficiency in using the insulin, pose significant health threats. These conditions can be mitigated in renal disease patients via fluid and electrolyte level management, blood pressure regulation, and dialysis, which eliminates waste products from the body, contributing to general health improvements, weight loss, and better blood sugar control. For example, as recorded by World Obesity in March 2022, a U.S. membership organization focused on studying and managing obesity, the population of obese individuals is anticipated to climb to 892 million by 2025 and further to 1,025 million by 2030. Additionally, the National Health Service, a publicly funded healthcare system based in the UK, projected in February 2023 that the number of UK residents suffering from diabetes could reach up to 5.5 million by 2030, affecting nearly 9% of the nation’s population. Consequently, the increasing trends in obesity and diabetes cases are anticipated to boost the ESRD drug market.
What Is The Overview Of Market Segmentation In The End Stage Renal Disease (ESRD) Drug Industry?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
How Are Key Trends Driving Expansion In The End Stage Renal Disease (ESRD) Drug Industry?
Introducing fresh products is a significant trend for achieving prominence in the end-stage renal disease (ESRD) drug market. Leading corporations in the ESRD drug sector are zeroing in on the production of inventive solutions to maintain their presence in the market. For instance, in April 2022, the US Food and Drug Administration (FDA) approved a New Drug Application (NDA) from GlaxoSmithKline PLC – a pharmaceutical and biotech company based in the UK. The application was for daprodustat, an orally consumed hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) – potentially catering to the treatment of patients with chronic kidney disease anemia (CKD). This innovative product is rooted in a unique Nobel prize-awarded scientific breakthrough that revealed how cells can detect and adjust to the levels of oxygen present.
Who Are The Primary Players Operating Across The Global End Stage Renal Disease (ESRD) Drug Market?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Get The Full Report Here:
Which Region Offers The Most Growth Potential For The End Stage Renal Disease (ESRD) Drug Market Through 2029?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model